Outcome of interval debulking in advanced ovarian cancer patients.

Interval debulking and neoadjuvant chemotherapy have been used in management of advanced epithelial ovarian cancer for many years in order to achieve optimal residual disease and reduce surgical morbidity. The present study was conducted to evaluate the outcomes of advanced ovarian cancer patients treated with these two approaches prior to cytoreductive surgery in Chiang Mai University Hospital between January 2001 and December 2006. The medical records of 29 patients who met the criteria were retrospectively reviewed. Most had stage IIIC serous cystadenocarcinomas. We found that the 5-year progression free survival and overall survival were 10% and 22% while the median values were 13 months and 34 months, respectively. Multivariate analysis showed that a suboptimal residual tumor volume was a statistically significant adverse prognostic factor for overall survival. In conclusion, interval debulking surgery and neoadjuvant chemotherapy before cytoreductive surgery lead to a more favorable outcome with advanced epithelial ovarian cancers.

Clinical outcomes and prognostic factors of node-negative cervical cancer patients with deep stromal invasion or lymphovascular space involvement following radical hysterectomy.

OBJECTIVE: To evaluate the clinical outcomes and prognostic factors of node-negative cervical cancer patients who had deep stromal invasion (DSI) and/or lymphovascular space invasion (LVSI) following radical hysterectomy and pelvic lymphadenectomy (RHPL). MATERIAL AND METHOD: The medical records of 150 node-negative stage IA2-IIA cervical cancer patients who had DSI and/or LVSI after RHPL from 1999 to 2004 were reviewed. RESULTS: Eighty-eight (58.4%) patients were treated with RHPL alone. Twenty-eight (18.7%), 23 (15.4%), eight (5.3%), and three (2%) patients received postoperative chemotherapy, chemoradiation, radiotherapy, and brachytherapy, respectively. Overall, 11 (7.3%) patients developed recurrence. The estimated 5-year disease-free survival of the patients was 90.9%. By multivariate analysis, two factors, age of less than 35 years old and a non squamous histology, were significantly independent prognostic. Eight (5.3%) patients experienced treatment-related complications. CONCLUSION: Node-negative cervical cancer patients with DSI and/or LVSI had excellent clinical outcomes. Young age and non-squamous histology are significant independent prognostic factors.